Please login to the form below

Not currently logged in

Pfizer partners with hospital to research medicines for children

Children’s Hospital of Philadelphia joins CTI translational research network

Children's Hospital of Philadelphia

Pfizer has teamed up with the Children's Hospital of Philadelphia (CHOP) to research new treatments for use in children.

The CHOP becomes the second paediatric centre to join Pfizer's Centers for Therapeutic Innovation (CTI) network, a translational research unit that aims to partner Pfizer scientists with academic researchers to bring investigational products to market more quickly.

As with other projects in the CTI, scientists from both Pfizer and CHOP will work together to identify preclinical research at the hospital that has potential to one day be a treatment.

Once identified, Pfizer said it will share with CHOP researchers its library of antibodies and other proteins, as well as its R&D tools. 

CHOP has already discussed the prospect with its researchers, and hopes to have the first proposals submitted by April 15.

In July 2013, a steering committee will then select which projects will receive fundraising, with the ultimate aim of advancing a paediatric project into a phase I clinical trial.

The steering committee for this includes Dr Philip Johnson, chief scientific officer and senior vice president of The Children's Hospital of Philadelphia, who welcomed the partnership.

He said: “We are excited to have this opportunity to accelerate the process of moving scientific insights toward therapies that healthcare providers can offer in the clinic”

The Massachusetts-headquartered CTI was launched as an open innovation network by Pfizer in 2010, offering external investigators access to relevant Pfizer compounds and technologies.

The first programme was a partnership between Pfizer and the University of California, San Francisco (UCSF), with the pharma company providing $85m of funding.

Including the partnership with CHOP, for which financial details were not released, there are now 21 academic medical institutions working with Pfizer as part of the CTI, such as Rockefeller University, Beth Israel Deaconess Medical Center and the University of California's San Diego Health Sciences.

Each deal is different, although Pfizer says the model creates “significant financial opportunities through milestones and royalties” for the academic institutions.

4th April 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...